Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 27827450 | HLA-B4 (BROAD ANTIGEN) | ocular toxoplasmosis | NA | NA | NA | unclassified | |
| the activating kir together with their hla ligands (kir3ds1-bw4-80ile and kir2ds1+/c2++ kir3ds1+/bw4-80ile+) were associated with increased susceptibility for ocular toxoplasmosis and its clinical manifestations. | |||||||
| 27827450 | HLA-B4 (BROAD ANTIGEN) | ocular toxoplasmosis | NA | NA | NA | negative | |
| kir-hla inhibitory pairs -kir2dl3/2dl3-c1/c1 and kir2dl3/2dl3-c1- were associated with decreased susceptibility for ocular toxoplasmosis and its clinical forms, while the kir3ds1-/kir3dl1+/bw4-80ile+ combination was associated as a protective factor against the development of ocular toxoplasmosis and, in particular, against recurrent manifestations. | |||||||
| 12652810 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | minimal residual disease | NA | NA | NA | positive | |
| in hematopoietic stem cell transplantation, hla(human leukocyte antigen) typing, assessment of graft viability/rejection (chimerism analysis), and evaluation of minimal residual disease are significant for treatment strategy. | |||||||
| 12652810 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | hematopoietic stem cell transplantation | NA | NA | NA | positive | |
| in hematopoietic stem cell transplantation, hla(human leukocyte antigen) typing, assessment of graft viability/rejection (chimerism analysis), and evaluation of minimal residual disease are significant for treatment strategy. | |||||||
| 27539576 | HLA MATCHED (HLA-MATCHED) | minimal residual disease | NA | NA | NA | unclassified | |
| it may thus be attractive to combine t cell immunotherapy of 'minimal residual disease/leukemia (mrd)' and cmv-specific t cell immunotherapy to combat both risks in hct recipients simultaneously, and ideally with t cells derived from the respective hla-matched hct donor. | |||||||
| 9620914 | HLA-B (HLA-B) | lung transplantation | NA | NA | NA | unclassified | |
| mismatches at the hla-dr and hla-b loci are risk factors for acute rejection after lung transplantation. | |||||||
| 9620914 | HLA-DR (HLA-DR) | lung transplantation | NA | NA | NA | unclassified | |
| mismatches at the hla-dr and hla-b loci are risk factors for acute rejection after lung transplantation. | |||||||
| 9620914 | HLA-B (HLA-B) | lung transplantation | NA | NA | NA | positive | |
| these results indicate that mismatches between donors and recipients at the hla-dr and hla-b loci are important risk factors for early high-grade rejections after lung transplantation. | |||||||
| 9620914 | HLA-DR (HLA-DR) | lung transplantation | NA | NA | NA | positive | |
| these results indicate that mismatches between donors and recipients at the hla-dr and hla-b loci are important risk factors for early high-grade rejections after lung transplantation. | |||||||
| 10678054 | HLA (HLA) | lung transplantation | NA | NA | NA | unclassified | |
| hla compatibility and transbronchial lung biopsy were important to the success of lung transplantation. | |||||||
Copyright 2024